While the biotech bear market has forced many companies to trim their pipelines, it’s less common to see a late-stage asset thrown on the scrapheap. But Kronos Bio has made that call for its acute myeloid leukemia (AML) drug entospletinib.
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...
Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid leukemia (AML) Additional presentations detail...